Biolinerx vs Shattuck Labs
Biolinerx is the larger business, with $1.2m of revenue in fiscal 2025 against $1.0m for Shattuck Labs (1.2 times as much). Shattuck Labs grew faster (-82.5% against -95.9%). Biolinerx kept more of each dollar of sales as profit: a net margin of -171.7% against -4880.9%. Biolinerx carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | BiolinerxBLRX, 2025 | Shattuck LabsSTTK, 2025 |
|---|---|---|
| Revenue | $1.2m | $1.0m |
| Revenue growth | -95.9% | -82.5% |
| Net income | −$2.0m | −$48.8m |
| Operating margin | -871.8% | -5150.8% |
| Net margin | -171.7% | -4880.9% |
| Return on equity | -12.8% | -60.3% |
| Free cash flow | −$8.1m | −$40.0m |
| Cash | $3.3m | $54.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 40 |
| Market value | $8.0m | $546m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 6 sales |